Abstract Library

#2955 Development of an EORTC Quality of Life Questionnaire for Patients with Pancreatic Neuroendocrine Tumours: Phases 1-3

Introduction: Measuring quality of life (QoL) in Pancreatic Neuroendocrine Tumours (pNET) involves assessing issues from symptoms, disease and treatment. The validated gastrointestinal NETs module (EORTC QLQ-GINET21) is used with EORTC QLQ-C30 but there are concerns it inadequately measures QoL in pNET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Friend E, Gray D, Fernández Ortega P, McNamara M, Kaltsas G,

Keywords: research, neuroendocrine, insulinoma, gastrinoma, non-functioning, VIPoma, Glucagonoma, questionnaire, quality of life,

#2826 NET-02: A Phase II Trial of Liposomal Irinotecan (nal-IRI) and 5-Fluorouracil (5-FU)/Folinic Acid or Docetaxel as Second-Line Therapy in Patients (pts) with Progressive Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma (PD-EP-NEC)

Introduction: The prognosis for pts with PD-EP-NEC is poor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: McNamara M

Authors: McNamara M, Swain J, Craig Z, Wadsley J, Wall L,

Keywords: poorly differentiated, neuroendocrine carcinoma, second line treatment, docetaxel, liposomal irinotecan, 5-fluorouracil,

#2034 International Survey of Clinical Practice Exploring Use of Platinum-Etoposide Chemotherapy for Extra-Pulmonary High Grade Neuroendocrine Carcinoma (EP-G3-NEC)

Introduction: Platinum-etoposide (PE) chemotherapy (CH) is a globally established combination for EP-G3-NEC; the optimal schedule has not been established.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Lamarca A

Authors: Lamarca A, Frizziero M, Barriuso J, McNamara M, Hubner R,

Keywords: high grade, neuroendocrine, survey, chemotherapy, platinum, etoposide,

#1872 Whole-Exome Sequencing (WES) of Samples from Patients (pts) Classified as Exceptional Responders (ER) vs Poor Responders (PO) to Targeted Therapies in Pancreatic Neuroendocrine Tumours (pNETs).

Introduction: Sunitinib (SU) and everolimus (EVE) changed the treatment landscape for patients with well-differentiated pNETs. However, no predictive biomarkers have been established for these drug

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Barriuso J, Lamarca A, McNamara M, Manoharan P, Moghadam S,

Keywords: pNETs, WES, everolimus, sunitinib,

#1492 Prospective Validation of Prognostic Score in High-Grade Gastrointestinal Neuroendocrine Carcinomas (GI-NECs)

Introduction: Prognostic markers for risk-stratification of GI-NECs are lacking.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Lamarca A

Authors: Lamarca A, Barriuso J, McNamara M, Hubner R, Valle J,

Keywords: NEC, score, overall survival, high grade, prognostic,